Last reviewed · How we verify
NCT05622851: RES
Comparative Ultrasound Analysis of Two Hyaluronic Acid Dermal Fillers
NA trial testing Restylane Contour in Volume Deficiency of the Midface in 11 participants. Completed in 6 December 2023.
25 September 2023
Quick facts
| Lead sponsor | Galderma R&D |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 12 July 2022 |
| Primary completion | 25 September 2023 |
| Estimated completion | 6 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Restylane Contour
- Juvederm Voluma
Conditions studied
- Volume Deficiency of the Midface — all drugs for Volume Deficiency of the Midface →
Sponsor
Galderma R&D — full company profile →
Who can join
Adults 22 to 65, any sex, with Volume Deficiency of the Midface. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess and compare tissue aggregation and visualization of two Hyaluronic Acid fillers via ultrasound
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Split-Face Comparison of Two Hyaluronic Acid Fillers: Intersection of Rheology and Tissue Behavior in Midface Rejuvenation.
Weiner SF, Hicks JA, Nguyen T, Meckfessel M. · · 2025 · cited 2× · PMID 40236885 · DOI 10.1093/asjof/ojaf006
Verify or expand the search:
- PubMed search for NCT05622851
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Restylane Contour
Trials testing the same drug.
- NCT05691972 — Effectiveness and Safety of Restylane Contour in the Treatment of Temple Hollowing · NA · completed
Other Galderma R&D trials
Trials by the same sponsor.
- NCT07047690 — A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis · Phase 2 · recruiting
- NCT07344584 — A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles · NA · not yet recruiting
- NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
- NCT07398989 — A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin · Phase 4 · completed
- NCT06988618 — Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05622851 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Galderma R&D
- Last refreshed: 22 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05622851.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing